#Saudi Arabia #Riyadh #Co-Diagnostics #CoMira #Arabian Eagle

Co-Diagnostics Partners with Arabian Eagle

Co-Diagnostics, Inc. (NASDAQ: CODX), a specialized molecular diagnostics firm, has reached a significant milestone by signing a definitive agreement with Arabian Eagle Manufacturing to form a joint venture known as CoMira Diagnostics. This new partnership aims to develop and localize Co-Dx's proprietary PCR platform throughout Saudi Arabia and 18 additional countries in the Middle East and North Africa (MENA).

A Strategic Move in Healthcare

The establishment of CoMira Diagnostics aligns perfectly with the objectives set out by Saudi Vision 2030, which emphasizes healthcare innovation, industrial diversification, and technology localization. CoMira will focus on the research, manufacturing, assembly, and distribution of Co-Dx technologies, including the innovative Co-Dx PCR point-of-care platform. This platform is designed to offer rapid and accurate diagnostics for a variety of infectious diseases, which will greatly benefit the healthcare landscape in the region.

Expanding Reach in the MENA Region

According to the agreement, CoMira Diagnostics will not only serve Saudi Arabia but will extend its offerings through the MENA region, covering countries like Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestine, Qatar, Syria, Turkey, the UAE, Yemen, Algeria, Egypt, Libya, Morocco, Sudan, and Tunisia. CEO Dwight Egan expressed enthusiasm, stating, "We are pleased to announce this agreement to establish the relationship with Arabian Eagle... to expand the reach of our exciting healthcare innovations into a region with a large and growing market for medical devices and point-of-care diagnostics."

Regulatory Approvals and Local Support

A critical aspect of the CoMira partnership is the collaboration with the Saudi Food & Drug Administration (SFDA). By obtaining regulatory clearances, CoMira aims to facilitate smoother entry into various other markets within the territory. Arabian Eagle Manufacturing will lead the charge in setting up manufacturing facilities, managing customer support, and ensuring compliance with local laws and regulations. This strategic local support framework is anticipated to bolster market penetration and streamline operations significantly.

Using Advanced Technologies to Enhance Healthcare

Arabian Eagle CEO, Ihssan Rjoob, highlighted the transformative nature of this partnership, which aims to utilize cutting-edge technologies such as artificial intelligence and machine learning. “This partnership represents a compelling model for combining international innovation with strong local leadership... delivering lasting impact across healthcare and manufacturing ecosystems,” Rjoob stated.

Future Developments and Innovations

Co-Diagnostics is preparing to begin clinical evaluations for various infectious disease tests as part of this partnership. Tests under consideration include screenings for tuberculosis, an eight-type HPV multiplex test, and a multiplex test for respiratory infections such as influenza A and B, COVID-19, and RSV. These evaluations are expected to commence before the end of 2025 in various jurisdictions, underscoring Co-Dx's commitment to innovation in molecular diagnostics.

Conclusion

With the launch of CoMira Diagnostics, Co-Diagnostics and Arabian Eagle are poised to make a significant contribution to the healthcare sector in the MENA region. This partnership not only supports the local economy but also aims to enhance health security through improved access to reliable diagnostic tools. Both companies are dedicated to empowering healthcare providers and patients alike, fulfilling unmet needs and aiming for better health outcomes across the region.